84 completed, 42 unknown, 19 recruiting, 18 terminated. 184 Phase 3, 20 Phase 2.
Follow Lymphoma, Large B-Cell, Diffuse: new trials by email Literature Review of Lymphoma, Large B-Cell, Diffuse trials Research Report on Lymphoma, Large B-Cell, Diffuse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma JS203 in combination with gemcitabine and oxaliplatin, Rituximab in combination with gemcitabine and oxaliplatin - Diffuse Large B-Cell Lymphoma | Phase 3 | Recruiting | Shanghai Junshi Bioscience Co., Ltd. | 282 | 2026-10-08 | 2026-10-14 |
| Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19) Birelentinib, Rituximab, Cyclophosphamid - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 / Phase 3 | Not yet recruiting | Dizal Pharmaceuticals | 880 | 2026-09-01 | 2026-08-05 |
| Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP Chidamide, Entecavir Tablets - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 3 | Recruiting | Ou Bai, MD/PHD | 200 | 2026-05-30 | 2026-03-25 |
| A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL HMPL-760, HMPL-760 Placebo, R-GemOx - Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Phase 3 | Recruiting | Hutchmed | 240 | 2026-03-20 | 2026-07-20 |
| A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy rondecabtagene autoleucel, axicabtagene ciloleucel, lisocabtagene maraleucel - Large B-cell Lymphoma, Lymphoma, B-Cell | Phase 3 | Recruiting | Lyell Immunopharma, Inc. | 400 | 2026-01-12 | 2026-08-04 |
| NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19) Talikabtagene Autoleucel - Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL), Relapsed/Refractory Non-Hodgkin Lymphoma | Phase 2 / Phase 3 | Recruiting | Health Institutes of Turkey | 40 | 2025-09-11 | 2026-03-30 |
| Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B Lymphoma Xinlikang capsules, mimic capsules - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 / Phase 3 | Recruiting | Sun Yat-sen University | 80 | 2025-09-11 | 2025-11-26 |
| A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma Purinostat Mesylate for Injection, Selinexor Tablets - Recurrent and Refractory Diffuse Large B-cell Lymphoma | Phase 3 | Recruiting | Chengdu Zenitar Biomedical Technology Co., Ltd | 390 | 2025-07-18 | 2025-09-19 |
| A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma SHR-A1912 Injection, Rituximab Injection, Gemcitabine Hydrochloride for Injection - Diffuse Large B-cell Lymphoma | Phase 3 | Active not recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 282 | 2025-04-24 | 2026-09-25 |
| A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) Zilovertamab vedotin, Rituximab, Cyclophosphamide - Diffuse Large B-Cell Lymphoma | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 1046 | 2025-01-27 | 2026-10-21 |
| Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Ifupinostat Hydrochloride for Injection, Rituximab Injection, Gemcitabine Hydrochloride for Injection - Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Phase 3 | Recruiting | BeBetter Med Inc | 416 | 2025-01-06 | 2026-08-19 |
| A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL Rituximab - Lymphoma, Large B-Cell, Diffuse | Phase 3 | Not yet recruiting | Xia Yi | 428 | 2024-08-23 | 2024-08-27 |
| Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma Dexrazoxane, Rituximab, Cyclophosphamide - DLBCL - Diffuse Large B Cell Lymphoma | Phase 3 | Recruiting | Stichting Hemato-Oncologie voor Volwassenen Nederland | 324 | 2024-08-15 | 2026-09-23 |
| A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Epcoritamab, Rituximab, Lenalidomide - Diffuse Large B-Cell Lymphoma | Phase 3 | Active not recruiting | Genmab | 379 | 2024-08-13 | 2026-04-08 |
| The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma polatuzumab vedotin, zanubrutinib, rituximab and lenalidomide, zanubrutinib, rituximab and lenalidomide - Diffuse Large B-Cell Lymphoma | Phase 3 | Recruiting | Ruijin Hospital | 100 | 2024-07-29 | 2024-08-05 |
| A Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment of EBV+ Diffuse Large B-cell Lymphoma R-CHOP, Decitabine in combination with R-CHOP - Lymphoma, Large-Cell, Diffuse | Phase 3 | Enrolling by invitation | Second Affiliated Hospital of Nanchang University | 80 | 2024-07-01 | 2026-01-16 |
| Maintenance Hormonal Therapy and DLBCL Tamoxifen 20mg - Diffuse Large B Cell Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | Sohag University | 100 | 2024-04-01 | 2024-04-09 |
| A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma Odronextamab, Rituximab, Cyclophosphamide - Diffuse Large B-cell Lymphoma (DLBCL) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 904 | 2023-12-13 | 2026-10-07 |
| Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma R-miniCHOP + Acalabrutinib, R-miniCHOP - Large B-cell Lymphoma, Diffuse Large B Cell Lymphoma | Phase 3 | Recruiting | Universität des Saarlandes | 330 | 2023-06-07 | 2026-06-29 |
| NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma NKTR-255 at 1.5 µg/kg, NKTR-255 at 3.0 μg/kg, NKTR-255 at 3.0/6.0 μg/kg - Non-Hodgkin Lymphoma, Relapsed/Refractory Diffuse Large B-cell Lymphoma | Phase 2 / Phase 3 | Terminated | Nektar Therapeutics | 15 | 2023-02-23 | 2026-10-16 |
Showing 20 of 184. Sign in to see all of them.
Lymphoma (66) · Lymphoma, Non-Hodgkin (65) · Lymphoma, Follicular (54) · Lymphoma, Large-Cell, Immunoblastic (49) · Lymphoma, Mantle-Cell (49) · Burkitt Lymphoma (47) · Leukemia, Lymphocytic, Chronic, B-Cell (42) · Lymphoma, B-Cell, Marginal Zone (41) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (40) · Hodgkin Disease (34) · Lymphoma, T-Cell, Cutaneous (27) · Multiple Myeloma (27) · Leukemia, Myeloid, Chronic-Phase (26) · Leukemia, Myeloid, Accelerated Phase (25)
Hemic and Lymphatic Diseases (184) · Immune System Diseases (183) · Neoplasms by Histologic Type (183) · Immunoproliferative Disorders (182) · Lymphatic Diseases (182) · Lymphoma, B-Cell (176) · Lymphoproliferative Disorders (176) · Neoplasms (170) · Lymphoma, Non-Hodgkin (119) · Lymphoma (118) · Pathologic Processes (52) · Pathological Conditions, Signs and Symptoms (52) · Hematologic Diseases (51) · Disease Attributes (50) · Leukemia, Lymphoid (48)
Rituximab (76) · Cyclophosphamide (54) · Doxorubicin (45) · Vincristine (44) · Prednisone (40) · Etoposide (24) · Gemcitabine (17) · Radiotherapy (15) · Cytarabine (12) · Filgrastim (12) · Lenalidomide (12) · Oxaliplatin (12) · Peripheral Blood Stem Cell Transplantation (12) · Carmustine (10) · Melphalan (10)
Lymphoma Study Association (8) · Hoffmann-La Roche (7) · Ruijin Hospital (7) · Fred Hutchinson Cancer Center (5) · European Organisation for Research and Treatment of Cancer - EORTC (4) · Fondazione Italiana Linfomi - ETS (4) · Genmab (4) · German High-Grade Non-Hodgkin's Lymphoma Study Group (4) · Incyte Corporation (3) · Jonsson Comprehensive Cancer Center (3) · Memorial Sloan Kettering Cancer Center (3) · NCIC Clinical Trials Group (3) · Nanfang Hospital, Southern Medical University (3) · National Cancer Institute (NCI) (3) · Novartis Pharmaceuticals (3)
United States (80) · China (63) · Italy (42) · France (41) · United Kingdom (39) · Belgium (35) · Canada (32) · Germany (32) · Spain (32) · Australia (31) · Poland (28) · Israel (27) · Czechia (25) · South Korea (25) · Switzerland (25)
Corinne Haioun, MD (3) · Brenda Sandmaier (2) · David J. Straus, MD (2) · John A. Glaspy, MD, MPH (2) · Michael G.M. Pfreundschuh, MD (2) · Michael G.M. Pfreundschuh, MD † (2) · Ru Feng, M.D. (2)
PMID 26373676, PMID 27282998, PMID 11807147, PMID 16754935, PMID 32499241, PMID 32817282, PMID 33288485, PMID 34515338, PMID 39563886, PMID 42699559, PMID 12419745, PMID 14998846, PMID 15459300, PMID 15621843, PMID 15659500, PMID 15867204, PMID 16148284, PMID 16449523, PMID 16648042, PMID 16710026, PMID 16879771, PMID 16888080, PMID 17071492, PMID 17397698, PMID 17400912, PMID 17439836, PMID 17654614, PMID 17785567, PMID 17889355, PMID 17971487, PMID 18005385, PMID 18065407, PMID 18226581, PMID 18256325, PMID 18293016, PMID 18400558, PMID 19270260, PMID 19636553, PMID 20007997, PMID 20371683, PMID 20548096, PMID 20660832, PMID 20708263, PMID 20735398, PMID 21482186, PMID 21495023, PMID 21707585, PMID 21895543, PMID 21940215, PMID 22118442
2023 (6), U10CA032102 (3), 2016 (2), 2017 (2), 2019 (2), P01CA015396 (2), P30CA006973 (2), P30CA015083 (2), P30CA015704 (2), P30CA068485 (2), 2008 (1), 2014 (1), 2015 (1), 2018 (1), P01CA018029 (1)